Skip to main content
. 2014 Jun 24;2014:349546. doi: 10.1155/2014/349546

Table 3.

Clinicopathologic factors affecting progression-free and overall survivals in 29 patients who showed underweight after treatment.

Characteristics Univariate Multivariate
HR 95% CI P value Adjusted HR 95% CI P value
Progression-free survival
 ≥53 years 1.91 0.79–4.63 0.15
 Stage IV disease 1.88 0.68–5.18 0.23 4.89 1.14–20.94 0.03
 Grade 3 disease 0.94 0.33–2.70 0.91
 Nonserous histology 2.99 1.13–7.90 0.03
 No neoadjuvant chemotherapy 1.54 0.51–4.64 0.45
 ≤6 cycles of adjuvant chemotherapy 1.10 0.40–3.01 0.86
 Suboptimal debulking surgery 3.89 1.55–9.74 <0.01 10.04 1.48–68.13 0.02
 Weight loss ≥10% 4.07 1.55–10.64 <0.01 6.90 1.51–31.54 0.01
Overall survival
 ≥53 years 2.07 0.62–6.92 0.24
 Stage IV disease 1.92 0.40–9.25 0.42 11.9 1.00–141.1 0.05
 Grade 3 disease 0.77 0.17–3.47 0.73
 Nonserous histology 2.58 0.73–9.15 0.14
 No neoadjuvant chemotherapy 1.27 0.27–6.02 0.77
 ≤6 cycles of adjuvant chemotherapy 3.84 0.78–18.91 0.10
 Suboptimal debulking surgery 2.64 0.88–7.91 0.08
 Weight loss ≥10% 12.81 2.54–64.65 <0.01 15.27 1.42–164.5 0.02